Tolvaptan (Otsuka)

Current Opinion in Investigational Drugs

Volumn 5, Issue 9, 2004, Pages 977-983

  Doggrell, Sheila A ^a  

^a Doggrell Biomedical Communications   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAZEPINE DERIVATIVE; DIURETIC AGENT; TOLVAPTAN; VASOPRESSIN RECEPTOR;

ANIMAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; HUMAN; METABOLISM; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZAZEPINES; CLINICAL TRIALS; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 16644388958     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. 273400 Drug development R&D pipeline: OPC-41061, OPC-31260. Otsuka Pharmaceutical Co Ltd COMPANY COMMUNICATION 1997 December 25
2. 2 receptors: Synthesis and pharmacological properties of 2-phenyl-4 (2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl benzanilide derivatives. Matsuhisa A, Tanaka A, Kikuchi K, Shimada Y, Yatsu T, Yanagisawa I CHEM PHARM BULL 1997 45 11 1870-1874
3. 2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H et al J PHARMACOL EXP THER 1998 287 3 860-877
4. 2 receptor antagonist. Kondo K, Ogawa H, Yamashita H, Miyamoto H, Tanaka M, Nakaya K, Kitano K, Yamamura Y, Nakamura S, Onogawa T, Mori T, Tominaga M BIOORG MED CHEM 1999 7 8 1743-1754
5. 2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Yatsu T, Tomura Y, Tahara A, Wada K, Kusayama T, Tsukada J, Tokioka T, Uchida W, Inagaki O, Iizumi Y, Tanaka A, Honda K EUR J PHARMACOL 1999 376 3 239-246
6. 2 receptor antagonist. Serradeil-Le Gal C ADV EXP MED BIOL 1998 449 427-438.
7. 2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T J PHARMACOL EXP THER 2000 292 1 288-294
8. 390778 Chronic effects of vasopressin receptor blockade with tolvaptan in congestive heart failure: A randomized, double-blind trial. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J I, Orlandi C CIRCULATION 2000 102 18 2869
9. 446506 Brain natriuretic peptide: Disease market or more in cardiovascular medicine? Doggrell SA DRUGS TODAY 2001 37 7 463-476
10. 2 vasopressin receptor antagonist, in patients with advanced heart failure. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, Ghali JK, Selaru P, Chanoine F, Pressler ML, Konstam MA et al CIRCULATION 2001 104 20 2417-2423.
11. 477612 The Otsuka R&D Pipeline. Otsuka Pharmaceutical Co Ltd COMPANY WORLD WIDE WEB SITE 2003 January 01
12. 512347 Otsuka's tolvaptan shows decreased fluid retention in hospitalized patients with worsening congestive heart failure. Otsuka Pharmaceutical Co Ltd PRESS RELEASE 2003 November 10
13. 2-receptor blockade with tolvaptan in patients with chronic heart failure - results from a double-blind, randomized trial. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J-I, Zampino M, Orlandi C CIRCULATION 2003 107 21 2690-2696
14. 513324 Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Gheorghiade M, Gattis WA, Barbagelata A, Adams KF Jr, Elkayam U, Orlandi C, O'Connor CM AM HEART J 2003 145 2 Suppl S51-S54
15. 513328 Tolvaptan has no effect on steady state amiodarone concentrations. Wang Z, Shoaf S, Kumara S, Mallikaarjun S, Orlandi C, Bramer S CLIN PHARMACOL THER 2003 73 2 Abs p44
16. 513340 Lack of effect of tolvaptan on pharmacokinetics (PK) and pharmacodynamics (PD) of warfarin. Wang Z, Shoaf S, Kumara S, Mallikaarjun S, Orlandi C, Bramer S CLIN PHARMACOL THER 2003 73 2 Abs p45
17. 513369 Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination. Udelson JE, Orlandi C, O'Brien T, Sequeira R, Ouyang J, Konstam MA J AM COLL CARDIOL 2002 39 5 Suppl A 156A
18. 2 vasopressin receptor antagonist, protects against the decline in renal function observed with loop diuretic therapy. Burnett JC, Smith WB, Ouyang J, Zimmer CA, Orlandi C CIRCULATION 2003 108 17 Abs 1841
19. 519304 The Otsuka R&D pipeline. Otsuka America Pharmaceuticals Inc COMPANY COMMUNICATION 2004 January 14
20. 520850 Yamanouchi submits New Drug Application to the FDA for YM 087 to treat hyponatremia. Yamanouchi Pharmaceutical Co Ltd PRESS RELEASE 2004 February 02
21. 2 receptor antagonist. Gatton VH 2nd, Wang X, Harris PC, Torres VE NAT MED 2003 9 10 1323-1326
22. 538701 Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH II NAT MED 2004 10 4 363-364
23. 538702 Vasopressin: A new target for the treatment of heart failure. Lee CR, Watkins ML, Patterson JH, Gattis W, O'Connor CM, Gheorghiade M, Adams KF Jr AM HEART J 2003 146 1 9-18
24. 538704 The evolving role of nesiritide in advanced or decompensated heart failure. Zineh I, Schofield RS, Johnson JA PHARMACOTHERAPY 2003 23 10 1266-1280
25. 2 receptor antagonist, SR121463, in cirrhotic rats. Jiménez W, Serradeil-Le Gal C, Ros J, Cano C, Cejudo P, Morales-Ruiz M, Arroyo V, Pascal M , Rivera F, Maffrand JP, Rodés J J PHARMACOL EXP THER 2000 295 1 83-90
26. 2 antagonist in cirrhotic patients with ascites. Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP HEPATOLOGY 2002 36 5 1197-1205.
27. 538759 Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the Registry Studies of Left Ventricular Dysfunction SOLVD Investigators. Benedict CR, Johnstone EE, Weiner DH, Bourassa MG, Bittner V, Kay R, Kirlin P, Greenberg B, Kohn RM, Nicklas JM et al J AM COLL CARDIOL 1994 23 6 1410-1420
28. 2 receptor antagonist. Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A NAUNYN-SCHMIEDEBERGS ARCH PHARMACOL 1998 357 1 63-69
29. 539280 Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jn, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C J AM MED ASSOC 2004 291 16 1963-1971
30. 539611 Edema and principles of diuretic use. Morrison RT MED CLIN NORTH AM 1997 81 3 689-704